Decision Support & Provider Education

Our decision support services are designed to present patient results in the clearest way possible and to provide information to help you establish a treatment plan. From interpretation of results on each report to expert consultations, we can help you ma

Streamlined Reports and Result Interpretation


Our reports provide information about your patient’s genomic findings and biomarkers and their associated targeted therapies and clinical trial options when available.

All Foundation Medicine CGP reports include a “Report Highlights” section on the first page, which summarizes actionable results in one easy-to-find bulletin-style box. Reports for FoundationOne®Liquid CDx also include historic patient findings from earlier Foundation Medicine tests, which allow you to follow your patients’ genomic profiles across the duration of their disease.

FoundationOne®CDx and FoundationOne®Liquid CDx Report Features

Genomic Alterations Our comprehensive genomic profiling tests analyze tumor tissue, blood, or bone marrow samples to identify clinically relevant genomic alterations. Therapies A patient’s report includes a list of targeted therapies or immunotherapies that match the genomic alterations and biomarkers identified in testing. Clinical Trials We also include relevant clinical trial options based on the patient’s genomic findings. Additional Biomarkers We also provide information aboutadditional biomarkers that may be associated with immunotherapy response.


Report Highlights

Summary of all actionable results in one easy-to-find bulletin-style box on the first page of the report. Personalized for each patient, helping you focus on the key results to inform your patient’s treatment plan.


Therapies With Clinical Benefit & Potential Resistance

Therapies may be matched to patient genomic alterations based on clinical guidelines and/or published literature. Therapy resistance based on your patient’s genomic profile will also be indicated.


FDA-Approved CDx Claims

Reports include a list of FDA-approved companion diagnostics, if available, to identify patients who may be eligible for treatment with associated therapies.


Clinical Trial Options

Detailed information about the clinical trials your patient has been matched to, ranked for the patient based on location and trial phase.

DS_02_CS Portrait 1.png

Discuss patient results with the Medical Affairs team at Foundation Medicine. This robust on-call program is covered by internal experts such as the Medical Science Liaison (MSL) team or by internal and external oncologists who are subject matter experts and consultants for Foundation Medicine.

  • Inquiries can be escalated via phone, email, or through the “Ask an Expert” portal 
  • Our team responds to over 200 inquiries per month
  • Inquiries are handled within 24-48 hours in 95% of cases
Provider Education

Molecular Tumor Boards (MTBs)

These virtual, educational meetings run by Foundation Medicine’s Medical Affairs team feature discussions about select test reports, the genomic alterations identified, and related implications. Foundation Medicine’s scientific and medical experts and care teams from cancer centers across the country work collaboratively to address the most complex cases.

Educational Benefits:

  • Awareness—Clinical case report interpretation increases awareness of CGP’s actionability
  • Data—FoundationCore database informs comprehension of complex cases
  • Understanding—Boards contribute to overall institutional knowledge of genomics and personalized cancer care
  • An institution physician-team presents the case history in a HIPAA-compliant manner
  • A genomicist and an oncologist or a pathologist representing Foundation Medicine discuss the associated genomics
  • Institution suggests ongoing MTB cadence (monthly or quarterly)

Questions? We’re Here to Help

Please contact our client services team by phone at +1(888) 988-3639 or by email at the link below.

Email Us